General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BVBDM
ADC Name
YTH24.5-SG3376
Synonyms
YTH24.5-SG3376
   Click to Show/Hide
Organization
CL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK; UCL Cancer Institute, 72 Huntley Street, London, UK.
Drug Status
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
YTH24.5
 Antibody Info 
Antigen Name
Undisclosed
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
 Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
SG3376
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.052
pM
CVCL_0065
T acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (lC50) 
0.096
pM
CVCL_2149
Acute erythroid leukemia
Half Maximal inhibitory Concentration (lC50) 
> 6000
pM
CVCL_0063
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.052 pM Positive CD45 expression (CD45+++/++)
Method Description
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.

   Click to Show/Hide
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.096 pM Positive CD45 expression (CD45+++/++)
Method Description
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.

   Click to Show/Hide
In Vitro Model Acute erythroid leukemia OCIM1 cells CVCL_2149
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 6000 pM Negative CD45 expression (CD45-)
Method Description
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.

   Click to Show/Hide
In Vitro Model Normal 293T cells CVCL_0063
References
Ref 1 Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant